bexarotene capsules — CareFirst (Caremark)
lymphomatoid papulosis (LyP)
Initial criteria
- Authorization may be granted for treatment as a single agent.
Reauthorization criteria
- Authorization may be granted if no evidence of unacceptable toxicity or disease progression while on current regimen.
Approval duration
12 months